title: [Cardiovascular morbidity associated with obstructive sleep apnea syndrome].
abstract: BACKGROUND
  The obstructive sleep apnoea syndrome (OSAS) had become a major public health concern in modern society due to its high prevalence but, above all, to its associated morbidity, especially cardiovascular.
  
  
  BACKGROUND
  Untreated OSAS is associated with an increased incidence of fatal (myocardial infarction and stroke) (odds ratio: 2.87) and non-fatal cardiovascular events (myocardial infarction, stroke, coronary artery bypass surgery and coronary angiography) (odds ratio: 3.17). Moreover, the prevalence of hypertension in patients with OSAS is high, between 35 and 80%. The pathophysiological mechanisms leading to these complications are mainly due to intermittent hypoxia secondary to repeated episodes of apnoea/hypopnoea during sleep. These mechanisms include sympathetic hyperactivation, impairment of vasomotor reactivity, vascular inflammation, oxidative stress and metabolic disorders. In patients with OSAS, the impact of continuous positive pressure is proven in terms of prevention of cardiovascular events although blood pressure reduction is limited. Obviously these effects are proportional to observance.
  
  
  CONCLUSIONS
  OSAS does increase the cardiovascular risk, independently of other risk factors. Although the impact of treatment is relatively low in decreasing blood pressure, it seems essentially effective in preventing cardiovascular morbidity. Therefore, OSAS screening, and the association of specific treatments in cardio-metabolic patients and OSAS patients respectively, should be included in clinical strategies.
authors.affiliation: Laboratoire HP2, université Grenoble Alpes, 38000 Grenoble, France; Laboratoire Inserm U1042, 38000 Grenoble, France; Clinique de pneumologie, CHU de Grenoble, 38000 Grenoble, France. Electronic address: mdestors@chu-grenoble.fr.
authors.forename: M
authors.initials: M
authors.lastname: Destors
authors.affiliation: Laboratoire HP2, université Grenoble Alpes, 38000 Grenoble, France; Laboratoire Inserm U1042, 38000 Grenoble, France; Pôle locomotion, rééducation et physiologie, laboratoire d'explorations fonctionnelles respiratoires et sommeil, clinique de physiologie, CHU de Grenoble, 38000 Grenoble, France.
authors.forename: R
authors.initials: R
authors.lastname: Tamisier
authors.affiliation: Unité d'hypertension artérielle, clinique de cardiologie, CHU de Grenoble, 38000 Grenoble, France.
authors.forename: J-P
authors.initials: JP
authors.lastname: Baguet
authors.affiliation: Laboratoire HP2, université Grenoble Alpes, 38000 Grenoble, France; Laboratoire Inserm U1042, 38000 Grenoble, France; Pôle locomotion, rééducation et physiologie, laboratoire d'explorations fonctionnelles respiratoires et sommeil, clinique de physiologie, CHU de Grenoble, 38000 Grenoble, France.
authors.forename: P
authors.initials: P
authors.lastname: Levy
authors.affiliation: Laboratoire HP2, université Grenoble Alpes, 38000 Grenoble, France; Laboratoire Inserm U1042, 38000 Grenoble, France; Pôle locomotion, rééducation et physiologie, laboratoire d'explorations fonctionnelles respiratoires et sommeil, clinique de physiologie, CHU de Grenoble, 38000 Grenoble, France.
authors.forename: J-L
authors.initials: JL
authors.lastname: Pepin
mesh_terms: D002317:Cardiovascular Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control; D002561:Cerebrovascular Disorders / Q000209:etiology / Q000517:prevention & control; D015897:Comorbidity; D045422:Continuous Positive Airway Pressure; D004730:Endothelium, Vascular / Q000503:physiopathology; D018149:Glucose Intolerance / Q000209:etiology; D006801:Humans; D006973:Hypertension / Q000453:epidemiology / Q000209:etiology; D000860:Hypoxia / Q000209:etiology / Q000517:prevention & control; D024821:Metabolic Syndrome / Q000209:etiology; D009569:Nitric Oxide / Q000096:biosynthesis; D009765:Obesity / Q000453:epidemiology; D018384:Oxidative Stress; D015995:Prevalence; D020181:Sleep Apnea, Obstructive / Q000150:complications* / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy; D013564:Sympathetic Nervous System / Q000503:physiopathology; D014657:Vasculitis / Q000209:etiology
chemical_list: D002317:Cardiovascular Agents; D009569:Nitric Oxide
keywords: Cardiovascular risk; Dysfonction vasculaire; Endothelial dysfunction; Facteur de risque cardiovasculaire; Hypertension; Hypertension artérielle; Hypoxia; Hypoxie; Sleep apnoea syndrome; Syndrome d’apnée du sommeil